Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

BioMarin Jumps as Drug Hits Goals: San Francisco Mover

Nov. 5 (Bloomberg) -- BioMarin Pharmaceutical Inc., a maker of drugs for rare diseases, rose to its highest value ever after its medicine for an enzyme deficiency disease met goals in a study, prompting plans to seek regulatory approval next year.

BioMarin jumped 31 percent to $49.07 in New York, its highest price since the shares began trading in July 1999, after releasing results today from the late-stage trial of its GALNS medicine. The Novato, California-based company has risen 43 percent this year.

The disease, mucopolysaccharidosis IVA, is also known as Morquio A syndrome, and it affects an estimated 2,500 to 3,000 patients worldwide, according to BioMarin. It can lead to short stature and problems in the joints, which may inhibit mobility. BioMarin’s drug, a replacement enzyme, helped patients walk 22.5 meters (73.8 feet) farther in six minutes than placebo, the primary goal of the study, the company said in a statement.

“We fully expect GALNS to be approved on the basis of this study,” Cory Kasimov, an analyst with JPMorgan Chase & Co. in New York, wrote in a note to clients. “We view the result as clearly positive for BioMarin and see it as a best-case outcome.”

The drug was generally well-tolerated in the trial, the third and final phase generally required for regulatory approval. GALNS also helped with secondary goals of the study, including improvement in a three-minute stair climb and reduction in urinary keratan sulfate levels, a measure of the presence of the enzyme.

“The GALNS clinical program is currently the highest development priority at BioMarin, and this positive Phase 3 study serves as a potentially transformative milestone for the company,” BioMarin Chief Executive Jean-Jacques Bienaimé said in the statement.

To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.